Cargando…
Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report
Neuroblastoma (NB) is a neural crest-derived malignant tumor which is diagnosed during infancy in approximately 40% of cases; spontaneous regressions are observed, but there are varying degrees of severity. Treatment is indicated if an infant’s condition is at risk of deterioration. Herein, we repor...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217743/ https://www.ncbi.nlm.nih.gov/pubmed/37238419 http://dx.doi.org/10.3390/children10050871 |
_version_ | 1785048611230318592 |
---|---|
author | Kato, Yutaka Kawaguchi, Hiroshi Sakata, Naoki Ueda, Satoshi Okano, Munehiro Nishino, Yuuki Ryujin, Masako Takemura, Yutaka Takemura, Tsukasa Sugimoto, Keisuke Okada, Satoshi |
author_facet | Kato, Yutaka Kawaguchi, Hiroshi Sakata, Naoki Ueda, Satoshi Okano, Munehiro Nishino, Yuuki Ryujin, Masako Takemura, Yutaka Takemura, Tsukasa Sugimoto, Keisuke Okada, Satoshi |
author_sort | Kato, Yutaka |
collection | PubMed |
description | Neuroblastoma (NB) is a neural crest-derived malignant tumor which is diagnosed during infancy in approximately 40% of cases; spontaneous regressions are observed, but there are varying degrees of severity. Treatment is indicated if an infant’s condition is at risk of deterioration. Herein, we report the case of a 42-day-old boy who presented with hepatomegaly and was diagnosed with stage MS NB. A pathological diagnosis of “poorly differentiated neuroblastoma with low mitosis-karyorrhexis index, favorable histology” was made; his tumor cells were hyperdiploid and MYCN was not amplified. Because he had respiratory distress caused by the rapidly evolving hepatomegaly, two cycles of chemotherapy containing vincristine and cyclophosphamide were administered in the second and fourth weeks of admission; however, his abdominal tumor did not shrink. In the sixth week of admission, chemotherapy was revised to pirarubicin and cyclophosphamide, and the tumor began to shrink. After discharge, there was no re-elevation of tumor markers; after 1 year, the hepatomegaly and liver metastases disappeared. During the 5-year follow-up, his growth and development were normal and he progressed without sequelae. A regimen that includes pirarubicin could merit further study in the treatment of early infants with stage MS low-risk NB who are at risk of complications. |
format | Online Article Text |
id | pubmed-10217743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102177432023-05-27 Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report Kato, Yutaka Kawaguchi, Hiroshi Sakata, Naoki Ueda, Satoshi Okano, Munehiro Nishino, Yuuki Ryujin, Masako Takemura, Yutaka Takemura, Tsukasa Sugimoto, Keisuke Okada, Satoshi Children (Basel) Case Report Neuroblastoma (NB) is a neural crest-derived malignant tumor which is diagnosed during infancy in approximately 40% of cases; spontaneous regressions are observed, but there are varying degrees of severity. Treatment is indicated if an infant’s condition is at risk of deterioration. Herein, we report the case of a 42-day-old boy who presented with hepatomegaly and was diagnosed with stage MS NB. A pathological diagnosis of “poorly differentiated neuroblastoma with low mitosis-karyorrhexis index, favorable histology” was made; his tumor cells were hyperdiploid and MYCN was not amplified. Because he had respiratory distress caused by the rapidly evolving hepatomegaly, two cycles of chemotherapy containing vincristine and cyclophosphamide were administered in the second and fourth weeks of admission; however, his abdominal tumor did not shrink. In the sixth week of admission, chemotherapy was revised to pirarubicin and cyclophosphamide, and the tumor began to shrink. After discharge, there was no re-elevation of tumor markers; after 1 year, the hepatomegaly and liver metastases disappeared. During the 5-year follow-up, his growth and development were normal and he progressed without sequelae. A regimen that includes pirarubicin could merit further study in the treatment of early infants with stage MS low-risk NB who are at risk of complications. MDPI 2023-05-12 /pmc/articles/PMC10217743/ /pubmed/37238419 http://dx.doi.org/10.3390/children10050871 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Kato, Yutaka Kawaguchi, Hiroshi Sakata, Naoki Ueda, Satoshi Okano, Munehiro Nishino, Yuuki Ryujin, Masako Takemura, Yutaka Takemura, Tsukasa Sugimoto, Keisuke Okada, Satoshi Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report |
title | Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report |
title_full | Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report |
title_fullStr | Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report |
title_full_unstemmed | Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report |
title_short | Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report |
title_sort | pirarubicin combination low-dose chemotherapy for early infantile stage ms neuroblastoma: case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217743/ https://www.ncbi.nlm.nih.gov/pubmed/37238419 http://dx.doi.org/10.3390/children10050871 |
work_keys_str_mv | AT katoyutaka pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport AT kawaguchihiroshi pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport AT sakatanaoki pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport AT uedasatoshi pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport AT okanomunehiro pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport AT nishinoyuuki pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport AT ryujinmasako pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport AT takemurayutaka pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport AT takemuratsukasa pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport AT sugimotokeisuke pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport AT okadasatoshi pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport |